Literature DB >> 33372854

SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species.

Mehdi Moustaqil1, Emma Ollivier1, Hsin-Ping Chiu2, Sarah Van Tol3, Paulina Rudolffi-Soto1, Christian Stevens2, Akshay Bhumkar1, Dominic J B Hunter1,4, Alexander N Freiberg5, David Jacques1, Benhur Lee2, Emma Sierecki1, Yann Gambin1.   

Abstract

The genome of SARS-CoV-2 encodes two viral proteases (NSP3/papain-like protease and NSP5/3C-like protease) that are responsible for cleaving viral polyproteins during replication. Here, we discovered new functions of the NSP3 and NSP5 proteases of SARS-CoV-2, demonstrating that they could directly cleave proteins involved in the host innate immune response. We identified 3 proteins that were specifically and selectively cleaved by NSP3 or NSP5: IRF-3, and NLRP12 and TAB1, respectively. Direct cleavage of IRF3 by NSP3 could explain the blunted Type-I IFN response seen during SARS-CoV-2 infections while NSP5 mediated cleavage of NLRP12 and TAB1 point to a molecular mechanism for enhanced production of cytokines and inflammatory responThe genome of SARS-CoV-2 encodes two viral proteases (NSP3/papain-like protease and NSP5/3C-like protease) that are responsible for cleaving viral polyproteins during replication. Here, we discovered new functions of the NSP3 and NSP5 proteases of SARS-CoV-2, demonstrating that they could directly cleave proteins involved in the host innate immune response. We identified 3 proteins that were specifically and selectively cleaved by NSP3 or NSP5: IRF-3, and NLRP12 and TAB1, respectively. Direct cleavage of IRF3 by NSP3 could explain the blunted Type-I IFN response seen during SARS-CoV-2 infections while NSP5 mediated cleavage of NLRP12 and TAB1 point to a molecular mechanism for enhanced production of cytokines and inflammatory response observed in COVID-19 patients. We demonstrate that in the mouse NLRP12 protein, one of the recognition site is not cleaved in our in-vitro assay. We pushed this comparative alignment of IRF-3 and NLRP12 homologs and show that the lack or presence of cognate cleavage motifs in IRF-3 and NLRP12 could contribute to the presentation of disease in cats and tigers, for example. Our findings provide an explanatory framework for indepth studies into the pathophysiology of COVID-19.

Entities:  

Keywords:  IRF3; NLRP12; NSP3 (PLpro); NSP5 (3CLpro); SARS-CoV-2; TAB1; innate immunity; protease activity

Mesh:

Substances:

Year:  2021        PMID: 33372854      PMCID: PMC7850364          DOI: 10.1080/22221751.2020.1870414

Source DB:  PubMed          Journal:  Emerg Microbes Infect        ISSN: 2222-1751            Impact factor:   7.163


  83 in total

1.  Clinical and immunological features of severe and moderate coronavirus disease 2019.

Authors:  Guang Chen; Di Wu; Wei Guo; Yong Cao; Da Huang; Hongwu Wang; Tao Wang; Xiaoyun Zhang; Huilong Chen; Haijing Yu; Xiaoping Zhang; Minxia Zhang; Shiji Wu; Jianxin Song; Tao Chen; Meifang Han; Shusheng Li; Xiaoping Luo; Jianping Zhao; Qin Ning
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

2.  p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1.

Authors:  Yue Ma-Lauer; Javier Carbajo-Lozoya; Marco Y Hein; Marcel A Müller; Wen Deng; Jian Lei; Benjamin Meyer; Yuri Kusov; Brigitte von Brunn; Dev Raj Bairad; Sabine Hünten; Christian Drosten; Heiko Hermeking; Heinrich Leonhardt; Matthias Mann; Rolf Hilgenfeld; Albrecht von Brunn
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-12       Impact factor: 11.205

3.  Pathological mutations differentially affect the self-assembly and polymerisation of the innate immune system signalling adaptor molecule MyD88.

Authors:  Ailís O'Carroll; Brieuc Chauvin; James W P Brown; Ava Meagher; Joanne Coyle; Jurgen Schill; Akshay Bhumkhar; Dominic J B Hunter; Thomas Ve; Bostjan Kobe; Emma Sierecki; Yann Gambin
Journal:  BMC Biol       Date:  2018-12-24       Impact factor: 7.431

Review 4.  Regulating IRFs in IFN Driven Disease.

Authors:  Caroline A Jefferies
Journal:  Front Immunol       Date:  2019-03-29       Impact factor: 7.561

5.  Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.

Authors:  Wenhao Dai; Bing Zhang; Xia-Ming Jiang; Haixia Su; Jian Li; Yao Zhao; Xiong Xie; Zhenming Jin; Jingjing Peng; Fengjiang Liu; Chunpu Li; You Li; Fang Bai; Haofeng Wang; Xi Cheng; Xiaobo Cen; Shulei Hu; Xiuna Yang; Jiang Wang; Xiang Liu; Gengfu Xiao; Hualiang Jiang; Zihe Rao; Lei-Ke Zhang; Yechun Xu; Haitao Yang; Hong Liu
Journal:  Science       Date:  2020-04-22       Impact factor: 47.728

Review 6.  Viral Innate Immune Evasion and the Pathogenesis of Emerging RNA Virus Infections.

Authors:  Tessa Nelemans; Marjolein Kikkert
Journal:  Viruses       Date:  2019-10-18       Impact factor: 5.048

7.  Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus.

Authors:  Santhana G Devaraj; Nan Wang; Zhongbin Chen; Zihong Chen; Monica Tseng; Naina Barretto; Rongtuan Lin; Clarence J Peters; Chien-Te K Tseng; Susan C Baker; Kui Li
Journal:  J Biol Chem       Date:  2007-08-30       Impact factor: 5.157

8.  The SARS coronavirus papain like protease can inhibit IRF3 at a post activation step that requires deubiquitination activity.

Authors:  Krystal Matthews; Alexandra Schäfer; Alissa Pham; Matthew Frieman
Journal:  Virol J       Date:  2014-12-07       Impact factor: 4.099

Review 9.  Human coronaviruses with emphasis on the COVID-19 outbreak.

Authors:  Saraj Bahadur; Wenxing Long; Muhammad Shuaib
Journal:  Virusdisease       Date:  2020-05-12

10.  Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates.

Authors:  Yu Wai Chen; Chin-Pang Bennu Yiu; Kwok-Yin Wong
Journal:  F1000Res       Date:  2020-02-21
View more
  59 in total

Review 1.  Roles of Sialyl Glycans in HCoV-OC43, HCoV-HKU1, MERS-CoV and SARS-CoV-2 Infections.

Authors:  Nongluk Sriwilaijaroen; Yasuo Suzuki
Journal:  Methods Mol Biol       Date:  2022

2.  Enterovirus 3C Protease Cleaves TRIM7 To Dampen Its Antiviral Activity.

Authors:  Wenchun Fan; Matthew B McDougal; John W Schoggins
Journal:  J Virol       Date:  2022-09-15       Impact factor: 6.549

Review 3.  Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options.

Authors:  Mariem Znaidia; Caroline Demeret; Sylvie van der Werf; Anastassia V Komarova
Journal:  Viruses       Date:  2022-06-08       Impact factor: 5.818

Review 4.  The Evolutionary Dance between Innate Host Antiviral Pathways and SARS-CoV-2.

Authors:  Saba R Aliyari; Natalie Quanquin; Olivier Pernet; Shilei Zhang; Lulan Wang; Genhong Cheng
Journal:  Pathogens       Date:  2022-05-03

5.  Cleavage of the selective autophagy receptor SQSTM1/p62 by the SARS-CoV-2 main protease NSP5 prevents the autophagic degradation of viral membrane proteins.

Authors:  Yabin Zhang; Shiyan Liu; Qingjia Xu; Huihui Li; Kefeng Lu
Journal:  Mol Biomed       Date:  2022-06-03

Review 6.  Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds.

Authors:  Jiajie Zhu; Haiyan Zhang; Qinghong Lin; Jingting Lyu; Lu Lu; Hanxi Chen; Xuning Zhang; Yanjun Zhang; Keda Chen
Journal:  Drug Des Devel Ther       Date:  2022-04-08       Impact factor: 4.319

7.  Profiling COVID-19 Genetic Research: A Data-Driven Study Utilizing Intelligent Bibliometrics.

Authors:  Mengjia Wu; Yi Zhang; Mark Grosser; Steven Tipper; Deon Venter; Hua Lin; Jie Lu
Journal:  Front Res Metr Anal       Date:  2021-05-24

Review 8.  Science's Response to CoVID-19.

Authors:  Marcus J C Long; Yimon Aye
Journal:  ChemMedChem       Date:  2021-06-22       Impact factor: 3.540

Review 9.  Infection-induced inflammation from specific inborn errors of immunity to COVID-19.

Authors:  Cheng-Lung Ku; I-Ting Chen; Ming-Zong Lai
Journal:  FEBS J       Date:  2021-05-20       Impact factor: 5.622

Review 10.  Control of Innate Immune Activation by Severe Acute Respiratory Syndrome Coronavirus 2 and Other Coronaviruses.

Authors:  Thomas Kehrer; Adolfo García-Sastre; Lisa Miorin
Journal:  J Interferon Cytokine Res       Date:  2021-06       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.